{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:04:32Z","timestamp":1792623872982,"version":"4.5.0"},"reference-count":107,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Drug repurposing, that is, the identification of new therapeutic indications for existing medications, has been shown to be a cost-effective and time-efficient alternative to de novo drug development. This review provides a comprehensive overview of repurposed drugs in veterinary oncology, describing their mechanisms of action, current evidence of clinical benefit, and translational relevance. The therapeutic agents discussed include non-steroidal anti-inflammatory drugs (e.g., piroxicam), metabolic modulators (e.g., metformin), anti-parasitic drugs (e.g., fenbendazole), immunomodulators (e.g., thalidomide, oclacitinib), cardiovascular agents (e.g., propranolol, statins, losartan), and other compounds such as auranofin and disulfiram. A critical evaluation of the extant evidence-based data from preclinical research, naturally occurring tumor models, and clinical studies is provided, with particular emphasis on both the therapeutic potential and the current limitations. The present review also focused on combination strategies and multimodal protocols, where repurposed drugs may enhance the efficacy of chemotherapy, targeted therapies, or immunotherapy. Challenges to clinical implementation, including limited funding, regulatory and ethical considerations, and the need for well-designed, multi-institutional clinical trials, are discussed. Ultimately, drug repurposing represents a practical and translationally valuable approach to broaden therapeutic options, improve quality of life in companion animals, and advance comparative oncology by promoting progress that benefits both veterinary and human patients.<\/jats:p>","DOI":"10.3390\/vetsci12111067","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:51:43Z","timestamp":1762451503000},"page":"1067","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug Repurposing in Veterinary Oncology: Myth or Reality?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4487-5784","authenticated-orcid":false,"given":"Stefano","family":"Ciccarelli","sequence":"first","affiliation":[{"name":"Department of Veterinary Medicine, University of Bari \u201cAldo Moro\u201d, 70010 Valenzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Perrone","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Bari \u201cAldo Moro\u201d, 70010 Valenzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-3968","authenticated-orcid":false,"given":"Maria Alfonsa","family":"Cavalera","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, University of Bari \u201cAldo Moro\u201d, 70010 Valenzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3993-038X","authenticated-orcid":false,"given":"Antonio","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Harvest Veterinary Oncology Center, Kwai Fung, Kwai Chung, Kowloon, Hong Kong 999077, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Giuliano, A., Horta, R.S., Vieira, R.A.M., Hume, K.R., and Dobson, J. (2022). Repurposing Drugs in Small Animal Oncology. Animals, 13.","DOI":"10.3390\/ani13010139"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, N., Grimshaw, A.A., Axson, S.A., Choe, S.H., and Miller, J.E. (2022). Drug repurposing: A systematic review on root causes, barriers and facilitators. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08272-z"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: Identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","first-page":"51","article-title":"Drug Repositioning: A Review","volume":"4","author":"Deotarse","year":"2015","journal-title":"Int. J. Pharma Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1358\/dnp.2010.23.1.1440373","article-title":"The year\u2019s new drugs & biologics\u20142009","volume":"23","author":"Graul","year":"2010","journal-title":"Drug News Perspect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1377\/hlthaff.2014.1038","article-title":"The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs","volume":"34","author":"Kesselheim","year":"2015","journal-title":"Health Aff."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zafar, R., Safdar, I., Munir, A., Zahid, M.R., and Serfraz, S. (2025). Advantages, Challenges, and Impact of Drug Repurposing for Cancer Treatment, IntechOpen.","DOI":"10.5772\/intechopen.1008768"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.21873\/invivo.11429","article-title":"Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms","volume":"32","author":"Lavalle","year":"2018","journal-title":"In Vivo"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.32819\/2023.11009","article-title":"Efficacy of metformin treatment for bitches with the mammary gland carcinoma","volume":"11","author":"Bilyi","year":"2023","journal-title":"Theor. Appl. Vet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology\u2014Patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","first-page":"e2078","article-title":"Statins as anti-tumor agents: A paradigm for repurposed drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Saha, J., Kim, J.H., Amaya, C.N., Witcher, C., Khammanivong, A., Korpela, D.M., Brown, D.R., Taylor, J., Bryan, B.A., and Dickerson, E.B. (2021). Propranolol Sensitizes Vascular Sarcoma Cells to Doxorubicin by Altering Lysosomal Drug Sequestration and Drug Efflux. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.614288"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.3390\/cimb45110560","article-title":"Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma","volume":"45","author":"Jung","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_16","unstructured":"Locklear, M. (2025, November 03). Novel Cancer Vaccine Offers New Hope for Dogs\u2014And Those Who Love Them, Yale News, Available online: https:\/\/news.yale.edu\/2024\/03\/05\/novel-cancer-vaccine-offers-new-hope-dogs-and-those-who-love-them."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Giuliano, A. (2021). Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma. Biology, 11.","DOI":"10.3390\/biology11010054"},{"key":"ref_18","first-page":"506","article-title":"Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment","volume":"50","author":"Souza","year":"2009","journal-title":"Can. Vet. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1939-1676.1994.tb03232.x","article-title":"Piroxicam Therapy in 34 Dogs With Transitional Cell Carcinoma of the Urinary Bladder","volume":"8","author":"Knapp","year":"1994","journal-title":"J. Vet. Intern. Med."},{"key":"ref_20","first-page":"356","article-title":"Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer","volume":"62","author":"Mohammed","year":"2002","journal-title":"Cancer Res."},{"key":"ref_21","first-page":"133","article-title":"Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy","volume":"62","author":"Bradbury","year":"2021","journal-title":"Can. Vet. J."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Petrucci, G.N., Magalh\u00e3es, T.R., Dias, M., and Queiroga, F.L. (2024). Metronomic chemotherapy: Bridging theory to clinical application in canine and feline oncology. Front. Vet. Sci., 11.","DOI":"10.3389\/fvets.2024.1397376"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1159\/000546362","article-title":"Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients","volume":"18","author":"Makis","year":"2025","journal-title":"Case Rep. Oncol."},{"key":"ref_24","first-page":"2","article-title":"Case Report Fenbendazole Enhancing Anti-Tumor Effect: A Case Series","volume":"4","author":"Chiang","year":"2021","journal-title":"Clin. Oncol. Case Rep."},{"key":"ref_25","first-page":"1284","article-title":"Fenbendazole as a Treatment for Diffuse Large B-Cell Lymphoma","volume":"7","author":"Abughanimeh","year":"2020","journal-title":"Ann. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Phan, P., Stapleton, S.L., Riggins, G.J., Koldobskiy, M.A., Raabe, E., and Cohen, K.J. (2025). Phase 1 study of mebendazole therapy for refractory\/progressive or recurrent pediatric brain tumors. Neurooncol. Pract., in press.","DOI":"10.1093\/nop\/npaf060"},{"key":"ref_27","first-page":"37","article-title":"Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins","volume":"47","author":"Gao","year":"2008","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","volume":"60","author":"DeCensi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/dom.12267","article-title":"The prognostic value of metformin for cancer patients with concurrent diabetes: A systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"eLife"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","article-title":"Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner","volume":"11","author":"Kalender","year":"2010","journal-title":"Cell Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3816\/CBC.2008.n.060","article-title":"Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer","volume":"8","author":"Goodwin","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3892\/ol.2021.13113","article-title":"Metformin inhibits the proliferation of canine mammary gland tumor cells through the AMPK\/AKT\/mTOR signaling pathway in vitro","volume":"22","author":"Fan","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10911-016-9370-7","article-title":"Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model","volume":"22","author":"Leonel","year":"2017","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.omto.2021.08.007","article-title":"Metformin preferentially enhances the radio-sensitivity of cancer stem-like cells with highly mitochondrial respiration ability in HMPOS","volume":"22","author":"Deguchi","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Barbieri, F., Thellung, S., Ratto, A., Carra, E., Marini, V., Fucile, C., Bajetto, A., Pattarozzi, A., W\u00fcrth, R., and Gatti, M. (2015). In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: Translational implications for human tumors. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1235-8"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Klose, K., Packeiser, E.M., M\u00fcller, P., Granados-Soler, J.L., Schille, J.T., Goericke-Pesch, S., Kietzmann, M., Murua Escobar, H., and Nolte, I. (2021). Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0257403"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rvsc.2017.03.003","article-title":"Anti-proliferative effect of metformin on a feline injection site sarcoma cell line independent of Mtor inhibition","volume":"114","author":"Pierro","year":"2017","journal-title":"Res. Vet. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/vco.12169","article-title":"Pilot study of oral metformin in cancer-bearing cats","volume":"15","author":"Wypij","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/vde.12047","article-title":"Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.rvsc.2018.10.014","article-title":"Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro","volume":"121","author":"Jaroszewski","year":"2018","journal-title":"Res. Vet. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Jasiecka-Miko\u0142ajczyk, A., Jaroszewski, J.J., and Ma\u015blanka, T. (2021). Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-\u03b3-, Producing Murine CD4+ and CD8+ T Cells and Counteracts the Induction of Type 1 Regulatory T Cells. Molecules, 26.","DOI":"10.3390\/molecules26185655"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/vde.13366","article-title":"Short-term administration of oclacitinib with concomitant medications in canine epitheliotropic lymphoma: A retrospective study of eight dogs","volume":"36","author":"Baba","year":"2025","journal-title":"Vet. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/vde.12976","article-title":"Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: A case report","volume":"32","author":"Aslan","year":"2021","journal-title":"Vet. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1292\/jvms.24-0432","article-title":"A case of lingual lymphoma in a dog treated with oclacitinib","volume":"87","author":"Nishimori","year":"2025","journal-title":"J. Vet. Med. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2736\/jjvd.30.147","article-title":"Epitheliotropic T-cell lymphoma arising around the paw of a dog responded well to oclacitinib","volume":"30","author":"Kan","year":"2024","journal-title":"Jpn. J. Vet. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"329","DOI":"10.56808\/2985-1130.1122","article-title":"Clinical response to oclacitinib in canine cutaneous epitheliotropic T-cell lymphoma: A case reports","volume":"53","author":"Imai","year":"2023","journal-title":"Thai J. Vet. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Barrett, L.E., Gardner, H.L., Barber, L.G., Sadowski, A., and London, C.A. (2019). Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: A pilot study. BMC Vet. Res., 15.","DOI":"10.1186\/s12917-019-2032-4"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.4142\/jvs.2020.21.e60","article-title":"Pharmacokinetics of thalidomide in dogs: Can feeding affect it? A preliminary study","volume":"21","author":"Pierini","year":"2020","journal-title":"J. Vet. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: A breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e38430","DOI":"10.7554\/eLife.38430","article-title":"Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome","volume":"7","author":"Donovan","year":"2018","journal-title":"eLife"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Belair, D.G., Lu, G., Waller, L.E., Gustin, J.A., Collins, N.D., and Kolaja, K.L. (2020). Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59542-x"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2183\/pjab.96.016","article-title":"Molecular mechanisms of thalidomide and its derivatives","volume":"96","author":"Ito","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/toxsci\/59.1.160","article-title":"Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs","volume":"59","author":"Teo","year":"2001","journal-title":"Toxicol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1292\/jvms.23-0200","article-title":"Safety and pharmacokinetics of thalidomide in tumor-bearing dogs","volume":"85","author":"Matsuyama","year":"2023","journal-title":"J. Vet. Med. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Bray, J.P., and Munday, J.S. (2020). Thalidomide Reduces Vascular Endothelial Growth Factor Immunostaining in Canine Splenic Hemangiosarcoma. Vet. Sci., 7.","DOI":"10.3390\/vetsci7020067"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: History and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res. C Embryo Today"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kowalski, T.W., Caldas-Garcia, G.B., Gomes, J.D.A., Fraga, L.R., Schuler-Faccini, L., Recamonde-Mendoza, M., Paix\u00e3o-C\u00f4rtes, V.R., and Vianna, F.S.L. (2021). Comparative Genomics Identifies Putative Interspecies Mechanisms Underlying Crbn-Sall4-Linked Thalidomide Embryopathy. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.680217"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (Review)","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jsap.12796","article-title":"Does thalidomide prolong survival in dogs with splenic haemangiosarcoma?","volume":"59","author":"Bray","year":"2018","journal-title":"J. Small Anim. Pract."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/vco.12393","article-title":"Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide","volume":"16","author":"Polton","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"ref_71","first-page":"3","article-title":"Abstracts from the ESVONC Annual Congress, 22\u201324 May 2025","volume":"23","author":"Ciccarelli","year":"2025","journal-title":"Vet. Comp. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","author":"Clendening","year":"2012","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1158\/0008-5472.CAN-08-2491","article-title":"Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells","volume":"69","author":"Slomiany","year":"2009","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Liu, C., Chen, H., Hu, B., Shi, J., Chen, Y., and Huang, K. (2023). New insights into the therapeutic potentials of statins in cancer. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1188926"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","article-title":"Statin drugs to reduce breast cancer recurrence and mortality","volume":"20","author":"Beckwitt","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1074\/jbc.M110.193714","article-title":"Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay between p53 and CD44","volume":"286","author":"Mandal","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3892\/or.2015.3850","article-title":"Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells","volume":"33","author":"Torres","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/s41388-021-02170-0","article-title":"Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment","volume":"41","author":"Goitea","year":"2022","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5603\/OCP.2022.0016","article-title":"Benefits of \u03b2-blockers in cancer treatment","volume":"19","author":"Arif","year":"2023","journal-title":"Oncol. Clin. Pract."},{"key":"ref_80","first-page":"680","article-title":"Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"801","DOI":"10.5455\/OVJ.2023.v13.i6.15","article-title":"Efficacy and adverse events of anthracycline and propranolol combination in five dogs with stage 3 hemangiosarcoma","volume":"13","author":"Terauchi","year":"2023","journal-title":"Open Vet. J."},{"key":"ref_82","unstructured":"Zaniboni, F., Sabattini, S., Romito, G., Mazzoldi, C., Chalfon, C., and Marconato, L. (2025). ESVONC-O-12: Use of propranolol in combination with chemotherapy in dogs with inoperable and\/or metastatic hemangiosarcoma. Proceedings of the 2025 European Society of Veterinary Oncology (ESVONC) Annual Congress, Oral Presentation."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Chauhan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"O\u2019Rawe, M., Kilmister, E.J., Mantamadiotis, T., Kaye, A.H., Tan, S.T., and Wickremesekera, A.C. (2021). The Renin\u2013Angiotensin System in the Tumor Microenvironment of Glioblastoma. Cancers, 13.","DOI":"10.3390\/cancers13164004"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1078-0432.CCR-21-2105","article-title":"Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma","volume":"28","author":"Regan","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/2767-9764.CRC-22-0388","article-title":"Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses","volume":"2","author":"Ammons","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"831","DOI":"10.18632\/oncotarget.5704","article-title":"Auranofin Is a Potent Suppressor of Osteosarcoma Metastasis","volume":"7","author":"Topkas","year":"2016","journal-title":"Oncotarget"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/vco.12619","article-title":"A prospective randomized trial of desmopressin in canine mammary carcinoma","volume":"18","author":"Sorenmo","year":"2020","journal-title":"Vet. Comp. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5326\/JAAHA-MS-5509","article-title":"Effect of Adjuvant Perioperative Desmopressin in Locally Advanced Canine Mammary Carcinoma and Its Relation to Histologic Grade","volume":"47","author":"Hermo","year":"2011","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Benavente, M.A., Bianchi, C.P., Imperiale, F., and Aba, M.A. (2016). Antiproliferative Effects of Oxytocin and Desmopressin on Canine Mammary Cancer Cells. Front. Vet. Sci., 3.","DOI":"10.3389\/fvets.2016.00119"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/vco.12636","article-title":"Effect of Perioperative Desmopressin in Cats with Mammary Carcinoma Treated with Bilateral Mastectomy","volume":"19","author":"Wood","year":"2021","journal-title":"Vet. Comp. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Xu, Y., Lu, L., Luo, J., Wang, L., Zhang, Q., Cao, J., and Jiao, Y. (2021). Disulfiram Alone Functions as a Radiosensitizer for Pancreatic Cancer Both In Vitro and In Vivo. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.683695"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.2147\/CMAR.S308168","article-title":"Overview of Antabuse\u00ae (Disulfiram) in Radiation and Cancer Biology","volume":"13","author":"Jia","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13643-021-01858-4","article-title":"Anticancer effects of disulfiram: A systematic review of in vitro, animal, and human studies","volume":"11","author":"Wang","year":"2022","journal-title":"Syst. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature25016","article-title":"Alcohol-Abuse Drug Disulfiram Targets Cancer via p97 Segregase Adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kannappan, V., Ali, M., Small, B., Rajendran, G., Elzhenni, S., Taj, H., Wang, W., and Dou, Q.P. (2021). Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.741316"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Gao, X., Huang, H., Pan, C., Mei, Z., Yin, S., Zhou, L., and Zheng, S. (2022). Disulfiram\/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma. Cancers, 14.","DOI":"10.3390\/cancers14194715"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/CM9.0000000000002909","article-title":"Disulfiram: A Novel Repurposed Drug for Cancer Therapy","volume":"137","author":"Zeng","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Lin, Z., Lin, Z., Zhou, C., Liu, G., Lin, J., Zhang, D., and Lin, D. (2021). Overexpression of Mucin 1 Suppresses the Therapeutical Efficacy of Disulfiram against Canine Mammary Tumor. Animals, 11.","DOI":"10.3390\/ani11010037"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2024.05.009","article-title":"A Phase 1\/2 Study of Disulfiram and Copper with Concurrent Radiation Therapy and Temozolomide for Patients with Newly Diagnosed Glioblastoma","volume":"120","author":"Huang","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ioakeim-Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza-Pascual-Salcedo, M., Gimeno-Miguel, A., Orlando, V., Gonz\u00e1lez-Rubio, F., Fanlo-Villacampa, A., Lasala-Aza, C., and Ostasz, E. (2023). Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials. Cancers, 15.","DOI":"10.3390\/cancers15112972"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacbts.2022.12.011","article-title":"Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use\u2014Patient Harms and Prescriber Responsibilities","volume":"8","year":"2023","journal-title":"JACC Basic Transl. Sci."},{"key":"#cr-split#-ref_105.1","unstructured":"European Union (2018). Regulation"},{"key":"#cr-split#-ref_105.2","unstructured":"(EU) 2019\/6 of the European Parliament and of the Council of 11 December 2018 on Veterinary Medicinal Products and Repealing Directive 2001\/82\/EC, European Union."},{"key":"ref_106","unstructured":"U.S. Government Publishing Office (GPO) (2025). Title 21-Food and Drugs Chapter I-Food and Drug Administration, Department of Health and Human Services Subchapter E-Animal Drugs, Feeds, and Related Products."}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/12\/11\/1067\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:19:49Z","timestamp":1762453189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/12\/11\/1067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":107,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["vetsci12111067"],"URL":"https:\/\/doi.org\/10.3390\/vetsci12111067","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}